换一批
换一批Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response.
第一作者：
Ho-Young,Yhim
第一单位：
Division of Hematology/Oncology, Department of Internal Medicine, Chonbuk National University Medical School, Deokjin-gu, Jeonju, Republic of Korea.
作者：
主题词
成年人(Adult);老年人(Aged);抗肿瘤药(Antineoplastic Agents);苯甲酰胺类(Benzamides);可行性研究(Feasibility Studies);女(雌)性(Female);随访研究(Follow-Up Studies);融合蛋白质类, bcr-abl(Fusion Proteins, bcr-abl);人类(Humans);白血病, 髓系, 慢性, BCR-ABL阳性(Leukemia, Myelogenous, Chronic, BCR-ABL Positive);男(雄)性(Male);中年人(Middle Aged);分子诊断技术(Molecular Diagnostic Techniques);肿瘤辅助疗法(Neoadjuvant Therapy);哌嗪类(Piperazines);嘧啶类(Pyrimidines);缓解诱导(Remission Induction);回顾性研究(Retrospective Studies);停止治疗(Withholding Treatment)
DOI
10.1016/j.leukres.2012.02.011
PMID
22398220
发布时间
2022-03-18
- 浏览4
Leukemia research
689-93页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
